Respiratory Medicine aims to provide a comprehensive platform for the publication of original research focused on diagnosis that affect the respiratory system.
Ensifentrine is a novel inhaled selective dual phosphodiesterase-3 (PDE3) and phosphodiesterase-4 (PDE4) inhibitor that is now approved in the United States for the treatment of stable chronic obstructive pulmonary disease (COPD)